Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDOCLOR-150 vs CARDURA XL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.
Hypertension
Benign prostatic hyperplasia (FDA-approved),Hypertension (FDA-approved)
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
15-22 hours in adults; terminal half-life is approximately 22 hours for extended-release formulation, allowing once-daily dosing. Half-life is prolonged in elderly and patients with hepatic impairment.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Extensively metabolized in the liver via CYP3A4 and CYP2D6; undergoes O-demethylation and hydroxylation.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Primarily hepatic metabolism via CYP3A4, with ~63% of the dose excreted in feces as metabolites and ~9% in urine as unchanged drug. Renal elimination of active drug is minimal (<1%).
Approximately 70-80% bound to plasma proteins, primarily albumin.
~98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
1.9-3.1 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
Oral extended-release: ~85% relative to immediate-release formulation, with minimal first-pass metabolism. Food does not significantly affect absorption.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
No dose adjustment required for renal impairment (GFR ≥30 m L/min). For GFR <30 m L/min, use with caution; no specific dose recommendation available.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), start at 2 mg once daily and titrate cautiously.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
Initiate at 2 mg once daily with breakfast; titrate slowly to avoid orthostatic hypotension. Monitor blood pressure closely.
None.
None.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Orthostatic hypotension and syncope, especially with first dose or dose increase,Priapism (rare),Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery,Hepatic impairment: dose adjustment may be needed
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Hypersensitivity to doxazosin or any component,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Avoid grapefruit and grapefruit juice as they may increase doxazosin concentrations. No other significant food interactions known. Alcohol may exacerbate hypotensive effects.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third trimesters: Potential for reduced placental perfusion due to alpha-blockade; avoid use unless benefit outweighs risk.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Unknown if excreted in human milk; M/P ratio not available. Caution advised; use only if clearly needed.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume. Use lowest effective dose and monitor clinical response.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
CARDURA XL (doxazosin extended-release) is an alpha-1 adrenergic blocker primarily used for benign prostatic hyperplasia (BPH). Its prolonged action reduces the risk of first-dose syncope compared to immediate-release. Do not crush or chew; swallow whole. Monitor blood pressure in patients also on antihypertensives due to additive hypotensive effects. Avoid use in patients with history of orthostatic hypotension or micturition syncope.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
Take exactly as prescribed, once daily with or without food. Swallow tablet whole, do not crush or chew.,Avoid grapefruit juice as it may alter drug levels.,Possible side effects include dizziness, fatigue, and nasal congestion. Rise slowly from sitting or lying to reduce fall risk.,May cause orthostatic hypotension especially after first dose or dose increase.,If you experience lightheadedness or fainting, contact your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDOCLOR-150 vs CARDURA XL, answered by our medical review team.
ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. CARDURA XL is a Alpha-1 Blocker Antihypertensive that works by Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDOCLOR-150 and CARDURA XL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. The standard adult dose of CARDURA XL is: 4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDOCLOR-150 and CARDURA XL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. CARDURA XL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.